These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 25525179)

  • 61. Untargeted plasma and tissue metabolomics in rats with chronic kidney disease given AST-120.
    Velenosi TJ; Hennop A; Feere DA; Tieu A; Kucey AS; Kyriacou P; McCuaig LE; Nevison SE; Kerr MA; Urquhart BL
    Sci Rep; 2016 Mar; 6():22526. PubMed ID: 26932318
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Activated fluid transport regulates bacterial-epithelial interactions and significantly shifts the murine colonic microbiome.
    Keely S; Kelly CJ; Weissmueller T; Burgess A; Wagner BD; Robertson CE; Harris JK; Colgan SP
    Gut Microbes; 2012; 3(3):250-60. PubMed ID: 22614705
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis.
    Chaves LD; McSkimming DI; Bryniarski MA; Honan AM; Abyad S; Thomas SA; Wells S; Buck M; Sun Y; Genco RJ; Quigg RJ; Yacoub R
    Am J Physiol Renal Physiol; 2018 Sep; 315(3):F487-F502. PubMed ID: 29693447
    [TBL] [Abstract][Full Text] [Related]  

  • 64. From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling.
    Vitetta L; Linnane AW; Gobe GC
    Toxins (Basel); 2013 Nov; 5(11):2042-57. PubMed ID: 24212182
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Short Chain Fatty Acids Effect on Chloride Channel ClC-2 as a Possible Mechanism for Lubiprostone Intestinal Action.
    Catalán MA; Julio-Kalajzić F; Niemeyer MI; Cid LP; Sepúlveda FV
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722648
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
    Lau WL; Savoj J; Nakata MB; Vaziri ND
    Clin Sci (Lond); 2018 Mar; 132(5):509-522. PubMed ID: 29523750
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exploring the Microbiome in Heart Failure.
    Kitai T; Kirsop J; Tang WH
    Curr Heart Fail Rep; 2016 Apr; 13(2):103-9. PubMed ID: 26886380
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
    Lembo AJ; Johanson JF; Parkman HP; Rao SS; Miner PB; Ueno R
    Dig Dis Sci; 2011 Sep; 56(9):2639-45. PubMed ID: 21769655
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
    Taguchi K; Fukami K; Elias BC; Brooks CR
    Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069405
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lubiprostone: chloride channel activator for chronic constipation.
    Rivkin A; Chagan L
    Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lanthanum hydroxide protects kidney through gut microbiota in a rat model of chronic kidney disease.
    Gao Y; Wang S; Sun L; Li B; Liu H; Bu R; Su C; Guo M; Liu Y; Zhao L; Gu C; Li X; Yuan X; Wang Q; Li G
    Pharmacol Res Perspect; 2024 Apr; 12(2):e1187. PubMed ID: 38546116
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lubiprostone: viewpoints.
    Schiller LR; Camilleri M
    Drugs; 2006; 66(6):880-1. PubMed ID: 16706563
    [No Abstract]   [Full Text] [Related]  

  • 73. Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine.
    Moeser AJ; Nighot PK; Roerig B; Ueno R; Blikslager AT
    World J Gastroenterol; 2008 Oct; 14(39):6012-7. PubMed ID: 18932279
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Uremic toxins and gut micro biome].
    Vaziri ND; Suematsu Y; Shimomura A; Vaziri ND
    Nihon Jinzo Gakkai Shi; 2017; 59(4):535-544. PubMed ID: 30620802
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lubiprostone induced ischemic colitis.
    Sherid M; Sifuentes H; Samo S; Deepak P; Sridhar S
    World J Gastroenterol; 2013 Jan; 19(2):299-303. PubMed ID: 23345954
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease.
    Mafra D; Lobo JC; Barros AF; Koppe L; Vaziri ND; Fouque D
    Future Microbiol; 2014; 9(3):399-410. PubMed ID: 24762311
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Psyllium seed husk regulates the gut microbiota and improves mucosal barrier injury in the colon to attenuate renal injury in 5/6 nephrectomy rats.
    Hu D; Liu W; Yu W; Huang L; Ji C; Liu X; Lu Z
    Ren Fail; 2023 Dec; 45(1):2197076. PubMed ID: 37017261
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Gut microbiome in chronic kidney disease.
    Wing MR; Patel SS; Ramezani A; Raj DS
    Exp Physiol; 2016 Apr; 101(4):471-7. PubMed ID: 26337794
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Novel intestinal dialysis interventions and microbiome modulation to control uremia.
    Sumida K; Lau WL; Kalantar-Zadeh K; Kovesdy CP
    Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):82-91. PubMed ID: 34846313
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preventive Effects of
    Huang H; Li K; Lee Y; Chen M
    J Agric Food Chem; 2021 Jul; 69(26):7353-7366. PubMed ID: 34170659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.